Related Experiment Video
Updated: Apr 14, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Vascular calcification in chronic kidney disease: an update
Georg Schlieper1, Leon Schurgers2, Vincent Brandenburg3
1Department of Nephrology, RWTH University of Aachen, Aachen, Germany.
Insights
Cardiovascular calcification, a risk factor for disease and death, accelerates in patients with chronic kidney disease or diabetes. Preventing this calcification by balancing promoters and inhibitors is key, as reversing it is difficult.
Area of Science:
- Cardiovascular research
- Nephrology
- Endocrinology
Background:
- Cardiovascular calcification contributes significantly to morbidity and mortality.
- Patients with chronic kidney disease and/or diabetes experience accelerated calcification in various cardiovascular tissues.
- Calcific uraemic arteriolopathy (calciphylaxis) is a rare but severe manifestation.
Purpose of the Study:
- To review the pathomechanisms of cardiovascular calcification, particularly in chronic kidney disease and diabetes.
- To discuss current therapeutic strategies focusing on prevention.
- To highlight the challenges and current research in the therapeutic regression of established calcifications.
Main Methods:
- Review of existing literature on cardiovascular calcification.
- Analysis of pathomechanistic pathways involving promoters and inhibitors.
- Examination of cellular processes in vascular calcification.
- Overview of therapeutic approaches and clinical trials.
Main Results:
- An imbalance of calcification promoters (calcium, phosphate) and inhibitors (fetuin-A, matrix Gla protein) is central to pathogenesis.
- Cellular processes, including vascular smooth muscle cell osteochondrogenesis and senescence, play a role.
- Preventive measures targeting the promoter-inhibitor balance are essential.
- Therapeutic regression of established cardiovascular calcification in humans is rarely reported.
Conclusions:
- Preventing cardiovascular calcification by correcting biochemical and cellular imbalances is crucial.
- Effective therapeutic strategies for reversing existing calcification are limited.
- Ongoing clinical trials are investigating secondary prevention in patients with established cardiovascular calcification.
Abstract:
Cardiovascular calcification is both a risk factor and contributor to morbidity and mortality. Patients with chronic kidney disease (and/or diabetes) exhibit accelerated calcification of the intima, media, heart valves and likely the myocardium as well as the rare condition of calcific uraemic arteriolopathy (calciphylaxis). Pathomechanistically, an imbalance of promoters (e.g. calcium and phosphate) and inhibitors (e.g. fetuin-A and matrix Gla protein) is central in the development of calcification. Next to biochemical and proteinacous alterations, cellular processes are also involved in the pathogenesis. Vascular smooth muscle cells undergo osteochondrogenesis, excrete vesicles and show signs of senescence. Therapeutically, measures to prevent the initiation of calcification by correcting the imbalance of promoters and inhibitors appear to be essential. In contrast to prevention, therapeutic regression of cardiovascular calcification in humans has been rarely reported. Measures to enhance secondary prevention in patients with established cardiovascular calcifications are currently being tested in clinical trials.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Skeleton and Calcium Homeostasis
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

